Djentinga

ADAP Bullish Divergence, Low Risk Play

Long
Djentinga Updated   
NASDAQ:ADAP   Adaptimmune Therapeutics plc
Bullish divergence on the MACD and ADX.

Price near last low.

Low risk play with high potential in the short term.
Comment:
Too tight stop. Let's see how this one plays out.
Trade closed: stop reached:
Not good enough
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.